FDA Finds Black Mold, Insects, and Serious Violations at GLP-1 Ingredient Factories

FDA Investigations Reveal Troubling Conditions at GLP-1 Drug Manufacturing Facilities

What Parker Waichman LLP Found

Based on the reported FDA inspection findings, Parker Waichman LLP identifies several important issues for patients considering legal action:

• Serious sanitation failures: Inspectors reportedly discovered mold, insects, and contaminated manufacturing areas.
• Questionable quality controls: Alleged document concealment, sample disposal, and inadequate ingredient verification raise safety concerns.
• Potential patient exposure: Ingredient distribution records are needed to determine whether affected materials reached U.S. compounders.
• Possible legal claims: Injured patients may have product liability or negligence claims when evidence connects their injuries to unsafe products.
• Time-sensitive evidence: Preserving medication packaging, pharmacy records, and medical documentation can be critical to investigating a lawsuit.

Millions of Americans have turned to GLP-1 medications to manage diabetes, lose weight, and address serious weight-related health conditions. Drugs containing semaglutide and tirzepatide have become increasingly popular, creating substantial demand for both FDA-approved medications and less expensive compounded alternatives. However, disturbing findings from federal inspections of two pharmaceutical manufacturing facilities in China have raised serious questions about the safety and quality of certain ingredients used to produce compounded GLP-1 medications. These findings include black mold on manufacturing equipment, insect activity, contaminated floors, questionable documentation practices, and failures to verify the quality of pharmaceutical ingredients.

According to an October 15, 2026, news report describing FDA inspection records obtained through a Freedom of Information Act request, investigators identified significant manufacturing and quality-control problems at Chengdu Shengnuo Biopharm Co. and Nanjing Chengong Pharmaceutical Co. Both companies manufactured active pharmaceutical ingredients associated with compounded versions of popular GLP-1 medications.

The findings are especially concerning because compounded medications do not undergo the same FDA premarket approval process required for commercially manufactured prescription drugs. Patients receiving these products may have limited information about where their active ingredients originated, how they were manufactured, or whether appropriate quality-control procedures were followed.

Although the inspection findings do not establish that every medication containing ingredients from these manufacturers was contaminated, they raise important questions about whether affected products entered the American pharmaceutical supply chain and whether patients experienced preventable injuries.

Black Mold, Insect Activity, and Unsanitary Manufacturing Conditions

One of the most troubling inspections involved Chengdu Shengnuo Biopharm Co., located in southwestern China. During an August 2026 inspection, FDA investigators reportedly discovered black mold on manufacturing equipment, significant insect activity in ceiling areas, and heavily contaminated floors.

These conditions raise substantial concerns about pharmaceutical manufacturing standards. Active pharmaceutical ingredients must be produced under controlled conditions designed to minimize contamination, prevent impurities, and maintain consistent product quality. Unsanitary facilities can create opportunities for microorganisms, foreign materials, and other contaminants to enter the manufacturing process.

For injectable medications, contamination concerns are particularly serious. Unlike medications taken orally, injections bypass several of the body’s natural protective barriers. If a contaminated injectable product reaches a patient, the consequences may include localized infections, inflammatory reactions, abscesses, or potentially life-threatening systemic infections.

The reported presence of mold and insects does not prove that finished medications were contaminated or that patients were injured. Determining whether contamination reached a particular product requires additional evidence, including manufacturing records, laboratory testing, distribution information, and potentially retained medication samples.

Nevertheless, these findings raise legitimate questions about whether appropriate safeguards were maintained during production and whether contaminated ingredients could have been distributed to pharmaceutical compounders.

FDA Inspectors Reportedly Witnessed Attempts to Conceal Documents and Destroy Samples

The inspection at Chengdu Shengnuo reportedly uncovered problems extending beyond unsanitary manufacturing conditions. According to the reported FDA findings, investigators observed quality-control employees carrying documents out of a laboratory and placing them inside lockers in another room.

Inspectors reportedly could not recover all the documents. They also observed personnel pouring product samples into sinks in what appeared to be a coordinated effort.

These allegations are significant because pharmaceutical manufacturing depends on accurate records and reliable testing. Manufacturers are expected to document production procedures, retain required quality-control information, investigate deviations, and maintain records supporting the identity, strength, quality, and purity of their ingredients.

Missing records or discarded samples can make it more difficult to determine whether a batch met applicable specifications. They may also complicate efforts to identify affected products and trace ingredients through distributors, compounding pharmacies, and healthcare providers.

For patients considering pharmaceutical injury lawsuits, these records could become important evidence. Attorneys may investigate whether manufacturing deficiencies contributed to a patient’s injuries, whether responsible companies knew about quality problems, and whether reasonable steps were taken to prevent potentially unsafe ingredients from reaching consumers.

Second Chinese Manufacturer Accused of Improper Ingredient Verification

FDA investigators reportedly identified a different set of problems during a September 2026 inspection of Nanjing Chengong Pharmaceutical Co., another manufacturer associated with the GLP-1 ingredient supply chain.

According to the inspection findings, employees purchased active pharmaceutical ingredients manufactured by other companies and applied Nanjing Chengong’s own approval documentation without adequately reviewing the original manufacturers’ testing information.

This practice raises concerns about ingredient traceability and quality verification. Pharmaceutical manufacturers must have reliable procedures to establish that materials meet applicable specifications. Improperly approving ingredients without sufficient verification can undermine the safeguards intended to identify impurities, incorrect ingredients, or products that fail quality standards.

When active ingredients move through multiple manufacturers, distributors, and compounding facilities, accurately documenting their origin becomes especially important. Incomplete or misleading records can make it difficult to determine which company actually produced an ingredient and whether that ingredient was properly tested.

The reported deficiencies do not establish that Nanjing Chengong distributed contaminated semaglutide or tirzepatide. However, they raise questions about the reliability of the company’s quality-control practices and the ability of downstream purchasers to verify ingredient safety.

FDA Import Alerts and the Risks Associated With Compounded GLP-1 Medications

Following the reported inspection findings, the FDA placed both manufacturers on import alerts, allowing federal authorities to detain covered products at the border without physical examination when applicable legal requirements are met.

Import alerts are important regulatory safeguards, but they are not equivalent to product recalls. They also do not establish that every ingredient previously supplied by a manufacturer was defective.

Compounded GLP-1 medications present additional regulatory considerations. FDA-approved drugs undergo a formal review of safety, effectiveness, manufacturing quality, and labeling. Compounded drugs are not FDA-approved, although legitimate compounding can serve important medical needs when performed under applicable federal and state requirements.

Compounding is generally intended to address specific patient needs, such as situations where an approved medication cannot meet a medically necessary requirement. Federal law also establishes restrictions on producing drugs that are essentially copies of commercially available medications.

The FDA determined that the shortages of tirzepatide and semaglutide injection products had been resolved in 2024 and 2025, respectively. The end of those shortages significantly restricted shortage-based compounding of copies, subject to applicable statutory requirements and enforcement policies.

Patients should also understand that the inspection findings concern particular ingredient manufacturers, not all GLP-1 medications. They do not establish contamination of FDA-approved Ozempic, Wegovy, Mounjaro, or Zepbound.

Potential Injuries From Contaminated or Improperly Manufactured GLP-1 Injections

Patients exposed to contaminated injectable medications may face serious health complications, depending on the nature of the contamination, the dose administered, and their underlying health conditions.

Potential complications can include injection-site infections, painful swelling, abscesses, fever, bloodstream infections, sepsis, and other serious inflammatory or infectious conditions. Improper manufacturing may also create concerns involving incorrect potency, chemical impurities, or inadequate ingredient verification.

An improperly formulated GLP-1 medication could potentially expose patients to excessive or insufficient amounts of an active ingredient. Excessive dosing may increase the risk of severe nausea, vomiting, dehydration, and other complications. However, these reactions can also occur with properly manufactured GLP-1 medications and do not independently establish contamination or negligence.

Anyone experiencing fever, spreading redness, severe injection-site pain, persistent vomiting, or other concerning symptoms after receiving a compounded GLP-1 injection should promptly seek medical evaluation. Symptoms suggesting a severe infection, including confusion, difficulty breathing, or fainting, require emergency care.

Medical testing and documentation can help determine the cause of an injury. Identifying the specific medication, manufacturer, lot number, pharmacy, and dates of administration may also be essential when investigating a potential pharmaceutical injury claim.

Legal Options for Patients Injured by Unsafe Compounded Weight-Loss Drugs

Patients who suffer injuries from contaminated or improperly manufactured compounded GLP-1 medications may have grounds to pursue compensation, depending on the facts and applicable state law.

Potential claims may involve pharmaceutical manufacturers, ingredient suppliers, distributors, compounding pharmacies, or other parties whose conduct contributed to an injury. The applicable legal theories may include product liability, negligence, failure to warn, breach of warranty, or pharmacy-related claims.

Establishing liability generally requires evidence connecting a specific product or negligent act to the patient’s injuries. An FDA inspection violation alone does not automatically establish that a patient has a valid lawsuit.

Relevant evidence may include medical records, laboratory results, pharmacy dispensing records, ingredient sourcing documents, manufacturing records, and product testing. Depending on the circumstances, attorneys may also examine whether the defendants complied with applicable pharmaceutical manufacturing and compounding requirements.

Compensation may include medical expenses, hospitalization costs, lost wages, diminished earning capacity, pain and suffering, and other legally recoverable damages. Families may also have wrongful death claims when a fatal injury is legally attributable to a defective medication or negligent conduct.

The availability and value of a claim depend on the patient’s circumstances, the responsible parties, causation evidence, and the laws governing the case.

Frequently Asked Questions About Contaminated GLP-1 Drug Lawsuits

Can I File a Lawsuit if I Became Sick After Taking Compounded Semaglutide or Tirzepatide?

You may have grounds to file a pharmaceutical injury lawsuit if a contaminated, defective, or improperly manufactured compounded GLP-1 medication caused your illness. Potential claims depend on the medication’s source, the nature of your injuries, and evidence establishing a connection between the product and your medical condition.

What Injuries Could Qualify for a Compounded GLP-1 Lawsuit?

Potential claims may involve serious infections, abscesses, sepsis, hospitalization, permanent organ damage, or other significant complications caused by contaminated or improperly manufactured medications. Severe adverse reactions resulting from incorrect potency or formulation errors may also warrant investigation.

How Can I Determine Whether My GLP-1 Medication Contained Ingredients From These Chinese Manufacturers?

Patients should contact their dispensing pharmacy and request information about the medication’s manufacturer, compounding facility, lot number, and available ingredient sourcing records. Prescription labels and receipts may identify the pharmacy but not the original ingredient manufacturer.

Can I Sue a U.S. Compounding Pharmacy for Contaminated Ingredients Imported From China?

A U.S. compounding pharmacy may face liability when its own negligent conduct or a legally actionable product defect contributes to a patient’s injury. Depending on applicable law, claims might involve improper sourcing, inadequate preparation, contamination, labeling errors, or other failures.

How Much Compensation Could I Receive From a Contaminated Weight-Loss Drug Lawsuit?

Compensation depends on the severity of the injuries, medical expenses, lost income, long-term health consequences, and applicable state law. Patients who require hospitalization or experience permanent disabilities may have substantially different damages from individuals who experience temporary complications.

Contact Parker Waichman LLP About a Potential Contaminated GLP-1 Drug Lawsuit

If you or a loved one suffered a serious infection, hospitalization, organ damage, or another significant medical complication after receiving compounded semaglutide or tirzepatide, you may have legal options. Manufacturing violations, questionable ingredient testing, and potentially unsafe pharmaceutical products deserve careful investigation, particularly when patients suffer preventable injuries.

At Parker Waichman LLP, our national personal injury law firm represents individuals and families harmed by dangerous medications, defective products, and corporate negligence. We can review the circumstances of your injury, investigate the medication’s manufacturing and distribution history, and determine whether you may have grounds to pursue compensation.

Call Parker Waichman LLP at 1-800-YOUR-LAWYER (1-800-968-7529) for a free consultation. Our firm assists injured individuals nationwide in evaluating potential pharmaceutical injury and product liability claims. Regardless of your location or where your injury occurred, our nationwide product injury law firm is ready to assist you.